These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 8829627)
1. Molecular analysis of the TP53 gene in Barrett's adenocarcinoma. Audrézet MP; Robaszkiewicz M; Mercier B; Nousbaum JB; Hardy E; Bail JP; Volant A; Lozac'h P; Gouérou H; Férec C Hum Mutat; 1996; 7(2):109-13. PubMed ID: 8829627 [TBL] [Abstract][Full Text] [Related]
2. TP53 gene mutations are rare in nondysplastic Barrett's esophagus. Novotna K; Trkova M; Pazdro A; Smejkal M; Soukupova A; Kodetova D; Smejkal P; Sedlacek Z Dig Dis Sci; 2006 Jan; 51(1):110-3. PubMed ID: 16416221 [TBL] [Abstract][Full Text] [Related]
3. Mutations of p53 in Barrett's esophagus and Barrett's cancer: a prospective study of ninety-eight cases. Schneider PM; Casson AG; Levin B; Garewal HS; Hoelscher AH; Becker K; Dittler HJ; Cleary KR; Troster M; Siewert JR; Roth JA J Thorac Cardiovasc Surg; 1996 Feb; 111(2):323-31; discussion 331-3. PubMed ID: 8583805 [TBL] [Abstract][Full Text] [Related]
4. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus. Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048 [TBL] [Abstract][Full Text] [Related]
5. TP53 mutations in malignant and premalignant Barrett's esophagus. Dolan K; Walker SJ; Gosney J; Field JK; Sutton R Dis Esophagus; 2003; 16(2):83-9. PubMed ID: 12823203 [TBL] [Abstract][Full Text] [Related]
6. TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. Hamelin R; Fléjou JF; Muzeau F; Potet F; Laurent-Puig P; Fékété F; Thomas G Gastroenterology; 1994 Oct; 107(4):1012-8. PubMed ID: 7523212 [TBL] [Abstract][Full Text] [Related]
7. P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus. Schneider PM; Stoeltzing O; Roth JA; Hoelscher AH; Wegerer S; Mizumoto S; Becker K; Dittler HJ; Fink U; Siewert JR Clin Cancer Res; 2000 Aug; 6(8):3153-8. PubMed ID: 10955797 [TBL] [Abstract][Full Text] [Related]
8. Intestinal differentiation and p53 gene alterations in Barrett's esophagus and esophageal adenocarcinoma. Moore JH; Lesser EJ; Erdody DH; Natale RB; Orringer MB; Beer DG Int J Cancer; 1994 Feb; 56(4):487-93. PubMed ID: 7906678 [TBL] [Abstract][Full Text] [Related]
9. p53 gene mutations in Barrett's epithelium and esophageal cancer. Casson AG; Mukhopadhyay T; Cleary KR; Ro JY; Levin B; Roth JA Cancer Res; 1991 Aug; 51(16):4495-9. PubMed ID: 1868473 [TBL] [Abstract][Full Text] [Related]
10. Mutation analysis of the p53, APC, and p16 genes in the Barrett's oesophagus, dysplasia, and adenocarcinoma. González MV; Artímez ML; Rodrigo L; López-Larrea C; Menéndez MJ; Alvarez V; Pérez R; Fresno MF; Pérez MJ; Sampedro A; Coto E J Clin Pathol; 1997 Mar; 50(3):212-7. PubMed ID: 9155671 [TBL] [Abstract][Full Text] [Related]
11. Clinical implications of p53 gene mutation in the progression of Barrett's epithelium to invasive esophageal cancer. Casson AG; Manolopoulos B; Troster M; Kerkvliet N; O'Malley F; Inculet R; Finley R; Roth JA Am J Surg; 1994 Jan; 167(1):52-7. PubMed ID: 8311140 [TBL] [Abstract][Full Text] [Related]
12. Adenocarcinoma arising in Barrett's oesophagus: evidence for the participation of p53 dysfunction in the dysplasia/carcinoma sequence. Hardwick RH; Shepherd NA; Moorghen M; Newcomb PV; Alderson D Gut; 1994 Jun; 35(6):764-8. PubMed ID: 8020801 [TBL] [Abstract][Full Text] [Related]
13. p53 immunoreactivity in Barrett's metaplasia, dysplasia, and adenocarcinoma--a case report. Kimura H; Konishi K; Kaji M; Maeda K; Yabushita K; Miwa A Hepatogastroenterology; 2001; 48(42):1662-4. PubMed ID: 11813596 [TBL] [Abstract][Full Text] [Related]
14. Molecular genetic analysis of surveillance biopsy samples from Barrett's mucosa--significance of sampling. Werther M; Saure C; Pahl R; Schorr F; Rüschoff J; Alles JU; Heinmöller E Pathol Res Pract; 2008; 204(5):285-94. PubMed ID: 18337019 [TBL] [Abstract][Full Text] [Related]
15. p53-mutant clones and field effects in Barrett's esophagus. Prevo LJ; Sanchez CA; Galipeau PC; Reid BJ Cancer Res; 1999 Oct; 59(19):4784-7. PubMed ID: 10519384 [TBL] [Abstract][Full Text] [Related]
16. Base transitions at CpG dinucleotides in the p53 gene are common in esophageal adenocarcinoma. Gleeson CM; Sloan JM; McGuigan JA; Ritchie AJ; Russell SE Cancer Res; 1995 Aug; 55(15):3406-11. PubMed ID: 7614480 [TBL] [Abstract][Full Text] [Related]
17. Overexpression of p53 protein in Barrett's syndrome with malignant transformation. Fléjou JF; Potet F; Muzeau F; Le Pelletier F; Fékété F; Hénin D J Clin Pathol; 1993 Apr; 46(4):330-3. PubMed ID: 8496390 [TBL] [Abstract][Full Text] [Related]
18. Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus. Zou H; Molina JR; Harrington JJ; Osborn NK; Klatt KK; Romero Y; Burgart LJ; Ahlquist DA Int J Cancer; 2005 Sep; 116(4):584-91. PubMed ID: 15825175 [TBL] [Abstract][Full Text] [Related]
19. Role of p53 assessment in management of Barrett's esophagus. Kubba AK; Poole NA; Watson A Dig Dis Sci; 1999 Apr; 44(4):659-67. PubMed ID: 10219819 [TBL] [Abstract][Full Text] [Related]